Publications scientifiques

Téléchargez nos documents

2015 Poster : T-cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC 2015

2015 Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis: Clinical and experimental Immunology

2015 Presentation : T-cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC 2015

2015 T cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC

2015 Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors: Cancer Biol Med

2015 Phase III, randomized trial of nivolumab versus docetaxel in advanced non-squamous cell NSCLC

2015 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer: The New England Journal of Medicine

2015 Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC

2015 Optimizing PD-L1 as a biomarker of response with pembrolizumab as first-line therapy for PD-L1–positive metastatic NSCLC

2014 Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing: PubMed

2014 The Dual Role of Myeloid- Derived Suppressor Cells in Liver Pathologies: Journal of Liver and Clinical Research

2014 Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival: Genome Research

2013 Erlotinib versus docetaxel as second-line treatment of patients with advanced NSCLC and wild-type EGFR tumours

2013 Increase in CD14+HLA-DR2/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis: Cancer Immunology-Immunotherapy

2013 Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma

2012 The Transcription Factor T-bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid Cells: Immunity

2012 Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study: Journal of Clinical Oncology

2012 Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, NSCLC with poor prognosis

1 2 3 4